Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: A case report and literature review

4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Immunotherapy has recently become a new focus for the treatment of malignant tumors following the surgery, chemotherapy, radiotherapy, and molecular targeted therapy. Nivolumab, a human monoclonal antibody, is the first programmed cell death protein-1 (PD-1) inhibitor, which can prohibit the interaction of its ligand (PD-L1), restoring the immune response of T cells, and enhancing the recognition of tumor cells by the immune system. Pulmonary carcinosarcoma is an uncommon but highly aggressive tumor type with a poor prognosis. We described a case of pulmonary carcinosarcoma, with the positive expression of PD-L1, obtained a significant benefit from Nivolumab treatment in a 64-year-old Chinese man, which give us a clue that patients with pulmonary carcinosarcoma may benefit fromanti-PD-1 immunotherapy.

Cite

CITATION STYLE

APA

Zhang, Z., Chen, Y., Ma, M., Hao, J., Ding, R., Han, L., … Zhao, M. (2017). Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: A case report and literature review. Oncotarget, 8(56), 96453–96459. https://doi.org/10.18632/oncotarget.19089

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free